Legal status · United States
Is Semaglutide with BPC-157 legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. Semaglutide with BPC-157 is not an approved medicine in the United States; its classification is "Not approved; research use only". Nothing containing it is authorized for any use in people. Vials labeled "for research use only" are not exempt: that label does not make human use lawful. On the evidence, 1 human study is cited on its profile.
Semaglutide with BPC-157 in the United States at a glance
| Classification | Not approved; research use only |
|---|---|
| Note | Semaglutide is FDA approved; BPC-157 is not approved and is not a permitted compounding ingredient, so the pairing is an approved drug alongside an unlawful one. |
| FDA approval status | Semaglutide is approved. BPC-157 is not approved and was reviewed by FDA staff in July 2026, who found no adequate human data and mislabelled products in the market. The combination has never been evaluated. |
| Human studies cited | 1 of 4 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Semaglutide with BPC-157 profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
No product containing Semaglutide with BPC-157 is approved by FDA for any use in the United States, so nothing on the market is authorized for people.
- 02
"Research use only" is a vendor label, not a legal category that permits human use. It does not exempt a product from medicines law.
- 03
Importing, supplying or promoting it for human use can fall under medicines legislation in the United States. This page is general information, not legal advice.
What Semaglutide with BPC-157 is
An approved drug with a 14.9% weight loss result paired with a peptide that FDA staff reviewed in 2026 and found had no adequate human data. The combination has never been tested. The stated reason for the pairing, that BPC-157 protects the gut or preserves muscle during rapid weight loss, has no trial behind it in any species for either claim.
This pairing exists because of a real problem. Rapid weight loss on a GLP-1 costs lean mass along with fat, and the gastrointestinal side effects are the main reason people stop.
Mechanism: Semaglutide acts at the GLP-1 receptor to reduce appetite and slow gastric emptying. BPC-157 is described in rodent work as promoting angiogenesis, upregulating growth hormone receptor expression and reducing inflammatory cytokines.
Regulatory history: Semaglutide is approved. BPC-157 is not approved and was reviewed by FDA staff in July 2026, who found no adequate human data and mislabelled products in the market. The combination has never been evaluated.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Semaglutide with BPC-157 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Semaglutide with BPC-157 in other countries
Frequently asked questions
Is Semaglutide with BPC-157 legal in the United States?
No. Semaglutide with BPC-157 is not an approved medicine in the United States; its classification is "Not approved; research use only". Nothing containing it is authorized for any use in people. Vials labeled "for research use only" are not exempt: that label does not make human use lawful. On the evidence, 1 human study is cited on its profile. Note: Semaglutide is FDA approved; BPC-157 is not approved and is not a permitted compounding ingredient, so the pairing is an approved drug alongside an unlawful one.
Can I buy Semaglutide with BPC-157 in the United States?
No approved product exists to buy. In the United States Semaglutide with BPC-157 is classified as "Not approved; research use only", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors. Note: Semaglutide is FDA approved; BPC-157 is not approved and is not a permitted compounding ingredient, so the pairing is an approved drug alongside an unlawful one.
Is Semaglutide with BPC-157 FDA approved?
No. FDA status: Semaglutide is approved. BPC-157 is not approved and was reviewed by FDA staff in July 2026, who found no adequate human data and mislabelled products in the market. The combination has never been evaluated.. Current US classification: "Not approved; research use only". On the evidence, 1 human study is cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Semaglutide with BPC-157 live on its compound profile.
Semaglutide with BPC-157 profileThis page is general information about the regulatory status of Semaglutide with BPC-157 in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.